Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
89.81 CHF | -0.63% | -3.71% | +5.82% |
Dec. 06 | Swiss Market Index Ends Week Little Changed; Holcim Shares Down | MT |
Dec. 06 | Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 47.5B | 48.66B | 51.63B | 50.54B | 45.44B | |||||
Other Revenues, Total | 1.18B | 1.24B | 1.25B | 1.28B | 1.22B | |||||
Total Revenues | 48.68B | 49.9B | 52.88B | 51.83B | 46.66B | |||||
Cost of Goods Sold, Total | 14B | 14.4B | 15.44B | 15.08B | 12.02B | |||||
Gross Profit | 34.68B | 35.5B | 37.44B | 36.74B | 34.64B | |||||
Selling General & Admin Expenses, Total | 14.32B | 14.09B | 14.82B | 14.19B | 12.49B | |||||
R&D Expenses | 8.44B | 8.55B | 9.15B | 9.25B | 9.01B | |||||
Other Operating Expenses | 575M | 670M | 653M | 449M | 498M | |||||
Other Operating Expenses, Total | 23.33B | 23.31B | 24.62B | 23.88B | 22B | |||||
Operating Income | 11.35B | 12.19B | 12.82B | 12.86B | 12.64B | |||||
Interest Expense, Total | -850M | -869M | -811M | -837M | -855M | |||||
Interest And Investment Income | 245M | 91M | 71M | 379M | 627M | |||||
Net Interest Expenses | -605M | -778M | -740M | -458M | -228M | |||||
Income (Loss) On Equity Invest. | 659M | 673M | 15.34B | -9M | -13M | |||||
Currency Exchange Gains (Loss) | -160M | -135M | -69M | -184M | -214M | |||||
Other Non Operating Income (Expenses) | -29M | -29M | -153M | -54M | 17M | |||||
EBT, Excl. Unusual Items | 11.22B | 11.92B | 27.2B | 12.15B | 12.2B | |||||
Restructuring Charges | - | - | - | - | -951M | |||||
Merger & Related Restructuring Charges | -68M | -89M | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 38M | 336M | 38M | -260M | -105M | |||||
Gain (Loss) On Sale Of Assets | 1.09B | 414M | 728M | 166M | 225M | |||||
Asset Writedown | -1.33B | -1.34B | -653M | -1.69B | -3.09B | |||||
Legal Settlements | -1.12B | -935M | -212M | -369M | 542M | |||||
Other Unusual Items | -882M | -431M | -965M | -1.63B | 296M | |||||
EBT, Incl. Unusual Items | 8.94B | 9.88B | 26.14B | 8.37B | 9.12B | |||||
Income Tax Expense | 1.79B | 1.81B | 2.12B | 1.42B | 551M | |||||
Earnings From Continuing Operations | 7.15B | 8.07B | 24.02B | 6.96B | 8.57B | |||||
Earnings Of Discontinued Operations | 4.59B | - | - | - | 6.28B | |||||
Net Income to Company | 11.74B | 8.07B | 24.02B | 6.96B | 14.85B | |||||
Minority Interest | -5M | 1M | 3M | - | -4M | |||||
Net Income - (IS) | 11.73B | 8.07B | 24.02B | 6.96B | 14.85B | |||||
Net Income to Common Incl Extra Items | 11.73B | 8.07B | 24.02B | 6.96B | 14.85B | |||||
Net Income to Common Excl. Extra Items | 7.14B | 8.07B | 24.02B | 6.96B | 8.57B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 5.12 | 3.54 | 10.71 | 3.19 | 7.15 | |||||
Basic EPS - Continuing Operations | 3.12 | 3.54 | 10.71 | 3.19 | 4.13 | |||||
Basic Weighted Average Shares Outstanding | 2.29B | 2.28B | 2.24B | 2.18B | 2.08B | |||||
Net EPS - Diluted | 5.06 | 3.52 | 10.63 | 3.17 | 7.1 | |||||
Diluted EPS - Continuing Operations | 3.08 | 3.52 | 10.63 | 3.17 | 4.1 | |||||
Diluted Weighted Average Shares Outstanding | 2.32B | 2.3B | 2.26B | 2.2B | 2.09B | |||||
Normalized Basic EPS | 3.06 | 3.27 | 7.58 | 3.48 | 3.67 | |||||
Normalized Diluted EPS | 3.02 | 3.24 | 7.52 | 3.46 | 3.64 | |||||
Dividend Per Share | 3.04 | 3.4 | 3.39 | 3.46 | 3.92 | |||||
Payout Ratio | 56.64 | 86.56 | 30.67 | 107.92 | 48.86 | |||||
American Depositary Receipts Ratio (ADR) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Supplemental Items | ||||||||||
EBITDA | 15.53B | 17.41B | 17.94B | 18B | 17.52B | |||||
EBITA | 14.19B | 15.65B | 16.73B | 16.84B | 16.6B | |||||
EBIT | 11.35B | 12.19B | 12.82B | 12.86B | 12.64B | |||||
EBITDAR | 15.55B | 17.42B | 17.95B | 18.01B | 17.53B | |||||
Effective Tax Rate - (Ratio) | 20.06 | 18.29 | 8.11 | 16.92 | 6.04 | |||||
Current Domestic Taxes | 1.19B | 932M | 958M | 617M | 1.14B | |||||
Current Foreign Taxes | 961M | 1.17B | 1.47B | 1.45B | 1.29B | |||||
Total Current Taxes | 2.15B | 2.1B | 2.43B | 2.07B | 2.43B | |||||
Deferred Domestic Taxes | 93M | 137M | -23M | 142M | -355M | |||||
Deferred Foreign Taxes | -447M | -430M | -286M | -797M | -1.52B | |||||
Total Deferred Taxes | -354M | -293M | -309M | -655M | -1.88B | |||||
Normalized Net Income | 7B | 7.45B | 17B | 7.6B | 7.62B | |||||
Interest Capitalized | 4M | 2M | 4M | 5M | 3M | |||||
Interest on Long-Term Debt | 66M | 67M | 62M | 60M | 62M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | - | - | - | - | - | |||||
General and Administrative Expenses | - | - | - | - | - | |||||
Research And Development Expense From Footnotes | 9.41B | 9.02B | 9.54B | 10B | 11.37B | |||||
Net Rental Expense, Total | 15M | 11M | 13M | 9M | 11M | |||||
Imputed Operating Lease Interest Expense | 3.33M | 2.27M | 2.45M | 2.05M | 2.78M | |||||
Imputed Operating Lease Depreciation | 11.67M | 8.73M | 10.55M | 6.95M | 8.22M | |||||
Stock-Based Comp., Other (Total) | 1.07B | 958M | 979M | 1.05B | 1.14B | |||||
Total Stock-Based Compensation | 1.07B | 958M | 979M | 1.05B | 1.14B |